News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Transdermal Rotigotine Improves Quality of Life in Patients with Parkinson's Disease: Presented at WPC, UCB Pharma (UCBJF.PK) Study


10/6/2010 12:21:09 PM

Doctor's Guide -- GLASGOW, Scotland -- October 5, 2010 -- Patients with Parkinson's disease (PD) who were treated with rotigotine for up to 12 weeks showed improvement in various activities of daily living, as well as in total health-related quality of life (HR-QOL), researchers said here at the 2nd World Parkinson Congress (WPC).

Read at Doctor's Guide

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES